Brief: GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer's Disease trial

GemVax & KAEL

23/11/2020 12:22

Nov 23 (Reuters) - GemVax & KAEL Co Ltd  082270.KQ :
    * GEMVAX & KAEL CO LTD - REPORTS FURTHER POSITIVE DATA FROM
GV1001
PHASE II ALZHEIMER'S DISEASE TRIAL
    * GEMVAX & KAEL CO LTD - NEWLY RELEASED DATA ALSO SHOWS A
STATISTICALLY SIGNIFICANT IMPROVEMENT IN NEUROPSYCHIATRIC
INVENTORY
    * GEMVAX & KAEL CO LTD -  NEWLY RELEASED DATA ALSO SHOWS AN
IMPROVEMENT TREND IN ALZHEIMER'S DISEASE COOPERATIVE
STUDY-ACTIVITIES OF DAILY LIVING
    * GEMVAX & KAEL CO LTD -  OTHER SECONDARY OUTCOME FOUND TO
BE
STATISTICALLY NOT SIGNIFICANT
    * GEMVAX & KAEL CO LTD -  PLANNING TO SUBMIT A PHASE III IND
APPLICATION FOR GV1001

Source text for Eikon:  ID:nPn4rqYjva 
Further company coverage:  082270.KQ 

 ((Reuters.Briefs@thomsonreuters.com;))